1. Introduction {#sec1}
===============

Acupuncture ([Figure 1(a)](#fig1){ref-type="fig"}), which utilizes fine needles to pierce through specific anatomical points (called "acupoints"), is an ancient traditional Chinese medical therapy that is used widely around the world \[[@B1]\]. The National Institutes of Health has defined acupuncture as "a family of procedures involving stimulation of anatomical locations on the skin by a variety of techniques" \[[@B2]\]. President Richard Nixon\'s visit to China in 1972 was the seminal event opening the door to Chinese medical practices. Since that time, there has been a growing interest in integrating acupuncture into Western medical practice. On November 16, 2010, acupuncture has been listed by UNESCO as "Intangible Cultural Heritage." Acupuncture uses a unique holistic approach to cure human diseases through establishment of equilibrium in the human life, body, mind, intellect, and soul, so satisfactory treatment results could be achieved \[[@B3]--[@B5]\]. Therapeutic effects of acupoint stimulation primarily work through 14 principal meridians ([Figure 1(b)](#fig1){ref-type="fig"}) that represent channels through which energy known as Qi flows \[[@B6]\]. Nowadays, this traditional Chinese medical technique has become very popular worldwide as a complementary medicine, and some of the common applications of acupuncture include heart disease, smoking cessation, and the treatment of inflammatory diseases and psychological disorders \[[@B7]--[@B10]\].

Acupuncture is a safe, traditional Chinese medical therapy that is often perceived as both calming and relaxing for patients. Human studies have found a physiological basis for acupuncture needling that involves both central and peripheral networks \[[@B11]\]. This understanding of the anatomical and physiologic nature of acupuncture points and meridians remains insufficient, and the challenge is therefore to clarify the true meaning. Although basic research on acupuncture has made considerable progress in the past 10 years, we still lack a clear picture of "how acupuncture works." We have to understand the traditional acupuncture and present it in the light of the 21st century scientific thoughts and experimental evidence. Metabolomics can capture global changes and overall physiological status in biochemical networks and pathways in order to elucidate sites of perturbations and has shown great promise as a means to identify biomarkers of disease \[[@B12]--[@B15]\]. It has become practically available and resembles acupuncture in many aspects that serves as the major driving force for translation of acupuncture medicine revolution into practice \[[@B16]\]. Metabolomics and acupuncturology are of some similar characteristics such as entirety, comprehensiveness, and dynamic changes. The area of integrating acupuncture with metabolomics approach has become a major hot of TCM research and will advance paving the road towards health care \[[@B17]\].

In traditional Chinese medicine (TCM), Zusanli (also known as ST-36, [Figure 1(b)](#fig1){ref-type="fig"}c) point of "The Stomach Meridian of Foot-Yangming" is commonly used in human acupuncture to treat a wide range of health conditions including gastrointestinal disorders such as stomach ache, abdominal pain and distension, constipation, diarrhea, vomiting, dysentery, indigestion, and others \[[@B18], [@B19]\]; however, little is understood about its biological basis and mechanism. Herein, the present study aims to gain a better insight into acupuncture-treated ST-36; low molecular-weight metabolite data were analyzed to detect the enriched clusters, to determine the perturbation pathways and to infer the biological processes. The specific and unique biochemical pathways can be identified and greatly facilitated by using multivariate statistical analysis methods.

2. Experimental Procedures {#sec2}
==========================

2.1. Chemicals and Reagents {#sec2.1}
---------------------------

Acetonitrile (HPLC grade) was purchased from Merck (Germany), respectively; the distilled water was produced by a Milli-Q ultrapure water system (Millipore, Billerica, USA); formic acid was of HPLC grade and obtained from Kermel Chemical Reagent Co., Ltd., China; leucine enkephalin was purchased from Sigma-Aldrich (St. Louis, MO, USA). All other reagents were of analytical grade.

2.2. Ethical Statement and Subjects {#sec2.2}
-----------------------------------

Written informed consents were obtained from all subjects. The experimental protocol was reviewed and approved by the Ethical Committee of Heilongjiang University of Chinese Medicine (no. HLJZY-2012-0198) and was conducted according to the principles expressed in the Declaration of Helsinki. Control subjects (*n* = 20) with a mean age ± SD of 25.4 ± 4.2 years were enrolled in this study from Heilongjiang University of Chinese Medicine, China. Acupuncture stimulation was performed on bilateral ST-36 for 30 min, once a day for two weeks. The outcomes of Health Survey Questionnaire were assessed, and the related clinical information including gender, age, body mass index, and main parameters was collected in Supplementary Table 1 (see Supplementary Material available online at <http://dx.doi.org/10.1155/2013/429703>).

2.3. Sample Preparation {#sec2.3}
-----------------------

The urine samples were collected at day points, and the endogenous metabolites were analyzed by an ultraperformance liquid chromatography-quadrupole time-of-flighthigh-definition mass spectrometry (UPLC-Q-TOF-HDMS). The subjects were given insulated ice packs in which they were asked to store the urine samples immediately until they were received by the study investigator. On arrival at the laboratory, the samples were centrifuged at 10,000 rpm for 10 min at 4°C to remove any solid debris. Fractions (10 mL) of the urine supernatants were then stored at −80°C until UPLC-Q-TOF-HDMS analysis. Thawed urine samples were collected after centrifugation at 13,000 rpm for 15 minutes at 4°C, and the supernatant was transferred to a 1.5 mL polypropylene tube and then filtered through a syringe filter (0.22 *μ*m); 5 *μ*L of the supernatant was injected into the UPLC-Q-TOF-HDMS.

2.4. Metabolic Profiling and Metabolite Analysis {#sec2.4}
------------------------------------------------

Chromatography was carried out with an ACQUITY UPLC BEH C~18~ column (100 mm × 2.1 mm, 1.7 *μ*m) using an ACQUITY UPLC system (Waters Corp., Milford, USA). A "purge-wash-purge" cycle was employed on the autosampler, with 90% aqueous formic acid used for the wash solvent and 0.1% aqueous formic acid used as the purge solvent; this ensured that the carryover between injections was minimized. The column was maintained at 50°C, and subsequently a gradient of 0.1% formic acid in acetonitrile (solvent A) and 0.1% formic acid in water (solvent B) was used as follows: a linear gradient of 0-1 min, 2% A; 1--5 min, 2--10% A; 5--7 min, 10--22% A; 7--11 min, 22--24% A; 11--16 min, 24--35% A; 16--18 min, 35--100% A. The flow rate was 0.50 mL/min, and 2 *μ*L aliquot of each sample was injected into the column. The eluent was introduced to the mass spectrometry directly, that is, without a split. Quality control samples were used to minimize the analytical variation, evaluate the compound stability, and monitor the sample preparation process. After every 10 sample injections, a pooled sample followed by a blank was injected in order to ensure consistent performance of the system.

The eluent was introduced into the Synapt High-Definition MS (Waters Corp., Milford, USA) analysis, and the optimal conditions were as follows: desolvation temperature of 350°C, source temperature of 110°C, sample cone voltage of 30 V, extraction cone voltage of 3.5 V for positive ion mode and 4.0 V negative ion mode, collision energy of 4 eV, microchannel plate voltage of 2400 V, cone gas flow of 50 L/h and desolvation gas flow of 700 L/h, and capillary voltage of 3.2 kV for positive ion mode and 2.6 kV negative ion mode. Centroid data was acquired between m/z 50 and 1000 using an accumulation time of 0.2 s per spectrum. For accurate mass acquisition, a lock mass of leucine enkephalin at a concentration of 200 pg/mL was used via a lock spray interface at a flow rate of 100 *μ*L·min^−1^ monitoring for positive ion mode (\[M + H\]^+^ = 556.2771) and negative ion mode (\[M − H\]^−^ = 554.2615) to ensure accuracy during the MS analysis.

The MassFragment application manager was used to facilitate the MS/MS fragment ion analysis process by way of chemically intelligent peak-matching algorithms. The identities of the specific metabolites were confirmed by comparison of their mass spectra and chromatographic retention times with those obtained using commercially available reference standards. This information was then submitted for database searching, either in-house or using the online ChemSpider database and MassBank data source.

2.5. Multivariate Data Analysis {#sec2.5}
-------------------------------

Centroid and integrated raw mass spectrometric data were processed using MassLynx V4.1 and MarkerLynx software (Waters Corp., Milford, USA). The intensity of each ion was normalized with respect to the total ion count to generate a data matrix that consisted of the retention time, m/z value, and the normalized peak area. The multivariate data matrix was analyzed by EZinfo software (Waters Corp., Milford, USA). The unsupervised segregation was checked by principal components analysis (PCA) using pareto-scaled data. With PCA, data were visualized by plotting the PC scores where each point in the scores plot represents an individual sample and the PC loadings where each point represents one mass/retention time pair. Potential markers of interest were extracted from S plots constructed following analysis with orthogonal partial least squares to latent structures discriminant analysis (OPLS-DA), and markers were chosen based on their contribution to the variation and correlation within the data set.

2.6. Construction and Analysis of Metabolic Pathway {#sec2.6}
---------------------------------------------------

The construction, interaction, and pathway analysis of potential biomarkers were performed with MetPA based on database source including the KEGG (<http://www.genome.jp/kegg/>) and Human Metabolome Database (<http://www.hmdb.ca/>) to identify the affected metabolic pathways analysis and visualization. Subsequently, the possible biological role was evaluated by the enrichment analysis using the MetaboAnalyst.

2.7. Statistical Analyses {#sec2.7}
-------------------------

SPSS 17.0 for Windows was used for the statistical analysis. The data were analysed using the Wilcoxon Mann-Whitney *U* Test, with *P* \< 0.05 set as the level of statistical significance.

3. Results {#sec3}
==========

3.1. Metabolomic Profiling {#sec3.1}
--------------------------

For UPLC-MS analysis, aliquots were separated using a Waters Acquity UPLC (Waters, Milford, MA) and analyzed using a Q-TOF/HDMS, which consisted of an electrospray ionization source and linear ion-trap mass analyzer. The UPLC-MS representative profiles of consecutively injected samples of the same aliquot showed stable retention time with no drift in all of the peaks (Supplementary Figure 1). The stable profiles reflected the stability of UPLC-HDMS analysis and reliability of the metabolomic data. Low molecular mass metabolites could be separated well in the short time of 18 min due to the minor particles (sub-1.7 *μ*m) of UPLC.

3.2. Pattern Recognition Analysis {#sec3.2}
---------------------------------

Both multivariate projection approaches such as PCA and OPLS-DA often can be taken, because of their ability to cope with highly multivariate, noisy, collinear, and possibly incomplete data. The PCA score plots showed that the metabolic profiles of the 7 and 14 days significantly changed as a result of acupuncture treatment (Figures [2(a)](#fig2){ref-type="fig"} and [3(a)](#fig3){ref-type="fig"}). Trajectory analyses of the urine samples in the three-dimensional score plots were corresponding to [Figure 1(b)](#fig1){ref-type="fig"} in positive mode and [Figure 2(b)](#fig2){ref-type="fig"} in negative mode. The ions that showed significant difference in abundance between the 0-day and 14-day treated humans were contributed to the observed separation (Figures [2(c)](#fig2){ref-type="fig"} and [3(c)](#fig3){ref-type="fig"}) and selected from the respective S plots as potential markers in positive and negative modes (Figures [2(d)](#fig2){ref-type="fig"} and [3(d)](#fig3){ref-type="fig"}). Overall 8236 retention time-exact mass pairs were determined in metabolomic profile of urine samples. VIP-value threshold cutoff of the metabolites was set to 2.0 and, above this threshold, were filtered out as potential biomarkers. Finally, the markers of significant contribution were characterized 30 in positive mode and 23 in negative mode ([Table 1](#tab1){ref-type="table"}). 53 metabolites were identified and verified by reference standards among the differential metabolites. From the above plots, various metabolites could be identified as being responsible for the separation between 0-day and 14-day groups and were therefore viewed as potential biomarkers.

3.3. Identification of Important Differential Metabolites {#sec3.3}
---------------------------------------------------------

The robust UPLC-HDMS analysis platform provides the retention time, precise molecular mass, and MS/MS data for the structural identification of biomarkers. The molecular mass was determined within measurement errors by Q-TOF, and meanwhile the potential elemental composition, degree of unsaturation, and fractional isotope abundance of compounds were also obtained. The presumed molecular formula was searched in ChemSpider, Human Metabolome Database, and other databases to identify the possible chemical constitutions, and MS/MS data were screened to determine the potential structures of the ions. According to the protocol detailed above, 53 endogenous metabolites contributing to the separation of the model group and control group were detected in the samples ([Table 1](#tab1){ref-type="table"}). Monitoring changes of these metabolites may predict the development of acupuncture-treated. Therefore, these metabolites were selected as candidate markers for further validation. Taking an example, the precise molecular weight is 263.1126, and the main fragment ions that were analyzed via the MS/MS screening and were observed in the negative ion spectrum. Its calculated molecular formula was speculated to be C~13~H~16~N~2~O~4~ based on the analysis of its elemental composition and fractional isotope abundance; the ion was inferred to be *alpha*-N-phenylacetyl-L-glutamine. Its mass spectrum is illustrated in [Figure 4(a)](#fig4){ref-type="fig"}. The precise molecular weight is 314.2790, and the main fragment ions that were analyzed via the MS/MS screening were observed in the positive ion spectrum ([Figure 4(b)](#fig4){ref-type="fig"}). Its calculated molecular formula was speculated to be C~17~H~31~NO~4~, and the ion was inferred to be 9-decenoylcarnitine.

3.4. Metabolic Pathway and Function Analysis {#sec3.4}
--------------------------------------------

More detailed analyses of pathways and networks influenced by acupuncture were performed by MetPA which is a free, web-based tool that combines result from powerful pathway enrichment analysis with the topology analysis. Metabolic pathway analysis with MetPA revealed that metabolites which were identified together were important for the host response to acupuncture-treated and were responsible for *alpha*-linolenic acid metabolism, d-glutamine and d-glutamate metabolism, citrate cycle (TCA cycle), alanine, aspartate, and glutamate metabolism, and vitamin B6 metabolism ([Figure 5](#fig5){ref-type="fig"} and Supplementary Table 2). Potential biomarkers were also identified from these relevant pathways. Some significantly changed metabolites have been found and used to explain the arachidonic acid metabolism. The detailed construction of the arachidonic acid metabolism pathways with higher score was shown in [Figure 5](#fig5){ref-type="fig"}. These results suggested that these pathways showed the marked perturbations over the entire time course of acupuncture-treated.

4. Discussion {#sec4}
=============

Acupuncture has been practiced in China for thousands of years as an important therapeutic method in TCM and has been gradually accepted in Western countries as an alternative or complementary treatment \[[@B21]\]. Acupuncture, a therapeutic modality with few or no adverse effects, is a nonpharmacological therapy in which needles are inserted at specific cutaneous locations of the body, known as acupoints, and has been widely used to reduce some symptoms or to treat diseases in clinical practice \[[@B22]\]. However, little is understood about its biological basis and how the acupuncture works. Extensive studies have been conducted on the mechanism of acupuncture to explain the effects of acupuncture on various systems and symptoms \[[@B23], [@B24]\]. Biomarkers are indicators of biological processes and pathological states that can reveal a variety of health and disease traits and could facilitate and improve the development of diseases treatments and benefit the public health \[[@B25]\]. It is important to note that the progress in metabolomics technology has provided sensitive, fast and robust tools to analyze biomarkers, within a biologic system \[[@B26]\]. It resembles TCM in many aspects such as study method and design and opens up a novel opportunity to reinvestigate TCM \[[@B27]\]. Therefore, combining metabolomics with in-depth investigations of acupuncture will enable a revolution in our understanding of disease and will advance personalized medicine. However, metabolomics analyses evaluating the physiological basis of acupuncture-treated human have yet not been examined. This study was therefore designed to further elucidate the underlying mechanism of acupuncture-treated man from the metabolic pathways in a global view.

In this study, metabolomic analysis of key regulatory metabolites in acupuncture-treated man was successfully investigated by UPLC-HDMS combined with multivariate statistical analysis. Interestingly, we have identified 53 specific metabolites relevant for ST-36. To examine the effect of the 0-day acupuncture on ST-36, global metabolomic profiles were compared between 0 day and 14 days. In total, 53 metabolites (33 decreased and 20 increased) were significantly changed. Five unique metabolic pathways were also indicated to be differentially affected in acupuncture-treated human. Of note, we found that acupuncture activated an array of factors involved in *alpha*-linolenic acid metabolism, TCA cycle, d-glutamine and d-glutamate metabolism, alanine, aspartate, and glutamate metabolism, and vitamin B6 metabolism pathways. The significantly downregulated and upregulated biomarkers were observed following the 14-day treatment. Metabolic analyses of acupuncture were inferred from changes in the intermediates during substance metabolism. Based on the findings of this study, it would appear that many different metabolic pathways were disrupted as a result of acupuncture on ST-36. In the present study, we describe the physiological basis and biological property of ST-36, which will help us understand the basic mechanisms of acupuncture. Integrated network analysis of the metabolites differentially expressed in acupuncture-treated yields highly related signaling networks and suggests strongly that the involvement of these signaling networks could be essential for the development of acupuncture. In its grandest vision, the application of metabolomics approaches to the study of acupuncture-perturbed networks will, through the identification of therapeutic drug targets, foster a future of personalized medicine. Biologically, several metabolite biomarkers for acupuncture treatment are revealed and serve as the candidates for further mechanism investigation. This topic is in progress as our further direction. Further integration of the data from other levels, such as gene expression and proteomics levels, will improve the robustness of the identified biomarker.

Metabolomics is a rapidly developing field that has given new hope in the treatment of acupuncture. With this change, it appears that all the ancient Chinese concepts can be reinterpreted and harmonized with the latest finding in metabolomic research. Application of metabolomic technologies to the study of the acupuncture will increase our understanding of the pathophysiological processes, and this should help us identify potential biomarkers to develop new therapeutic strategies. The rapid growth of metabolomics field provides an array of new tools for the integration of acupuncture with modern technology and systems biology and is potentially advancing the progress of modernization and internationalization of acupuncture \[[@B28]--[@B30]\]. More work needs to be performed to explore the molecular mechanisms underlying acupuncture, and this could lead to novel treatments to maximize the therapeutic benefits of acupuncture. Acupuncture medicine can take advantage of metabolomic framework to provide the healthcare system with useful tools that can optimize the effectiveness of treatment. Researchers believe that metabolomics has the potential to revolutionize the practice of acupuncture medicine, improve the diagnosis, prevention, and treatment of disease, and reduce adverse drug reactions.

5. Conclusions {#sec5}
==============

In order to realize the potential role of acupuncture, an intrinsic part of TCM, metabolomics technologies are being increasingly used for acupuncture medicine; efforts are in progress in major therapeutic areas. Furthermore, because of the dynamic nature of the metabolome and its responsiveness to perturbations associated with stimuli, greater understanding will be needed in key metabolites or metabolic pathways toward the elucidation of molecular mechanisms underlying. We have firstly constructed the metabolomic feature profiling and metabolite interaction network of ST-36 by using validated pattern recognition approach and ingenuity pathways analysis. Analyzing the topology of the network, we have detected 53 potential biomarkers and predicted the major metabolites network of ST-36. Combining the results from these methods, we have calculated five high confidence networks. The identified target metabolites were found to encompass a variety of pathways. The power of metabolomics to capture and elucidate metabolic characters of the ST-36 has been successfully demonstrated in this study. Our study also highlights the importance of metabolomics as a potential tool for uncovering metabolic pathways to assess acupuncture treatment. We expect that, in future, metabolomics would serve as "Trojan horses in the 21st century" in the field of acupuncture treatment.

Supplementary Material {#supplementary-material-sec}
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Supplementary Figure S1: UPLC-MS BPI urine chromatograms of acupuncture-treated human in positive mode (A) and negative mode (B).

Supplementary Table 1: Clinical characteristics of the healthy subjects at baseline.

Supplementary Table 2: Result from ingenuity pathway analysis.

###### 

Click here for additional data file.
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![Acupuncture (a) and acupoint map of human meridians (b). c: "Zusanli" acupoint (ST-36).](ECAM2013-429703.001){#fig1}

![PCA model results for control and model group in positive mode (a). Trajectory analysis of PCA score plots (3D) for the serum samples in positive mode (b). PCA model results for 0 day and 14 days in positive mode (c). VIP plot of OPLS-DA of samples in positive mode (d).](ECAM2013-429703.002){#fig2}

![PCA model results for control and model group in negative mode (a). Trajectory analysis of PCA score plots (3D) for the serum samples in negative mode (b). PCA model results for 0 day and 14 days in negative mode (c). VIPplot of OPLS-DA of samples in negative mode (d).](ECAM2013-429703.003){#fig3}

![Mass fragment information of *alpha*-N-phenylacetyl-L-glutamine in negative mode (a) and 9-decenoylcarnitine in positive mode (b).](ECAM2013-429703.004){#fig4}

![Construction of the arachidonic acid metabolism pathways in acupuncture-treated human. The map was generated using the reference map by KEGG (<http://www.genome.jp/kegg/>). The green boxes: enzymatic activities with putative cases of analogy in acupuncture-treated human. 1: *alpha*-linolenic acid metabolism; 2: D-glutamine and D-glutamate metabolism; 3: citrate cycle (TCA cycle); 4: alanine, aspartate, and glutamate metabolism; 5: vitamin B6 metabolism.](ECAM2013-429703.005){#fig5}

###### 

Potential biomarkers identified of acupuncture-treated human in positive and negative modes.

  No.   Rt (min)   *m*/*z* determined   *m*/*z* calculated   Error (mDa)   Ion form        Formula              Metabolite name                       VIP value   Trend   *P* value
  ----- ---------- -------------------- -------------------- ------------- --------------- -------------------- ------------------------------------- ----------- ------- -----------
  1     0.50       162.1126             162.1130             −0.4          \[M + H\]^+^    C~7~H~15~NO~3~       Carnitine                             5.1         ↑       0.0087
  2     2.32       290.1597             290.1604             −0.7          \[M + H\]^+^    C~13~H~23~NO~6~      3-Methylglutarylcarnitine             4.8         ↑       0.0431
  3     3.45       276.1815             276.1811             0.4           \[M + H\]^+^    C~13~H~25~NO~5~      Hydroxyhexanoycarnitine               3.4         ↑       0.0327
  4     4.77       265.1205             265.1188             1.7           \[M + H\]^+^    C~13~H~16~N~2~O~4~   *alpha*-N-Phenylacetyl-L-glutamine    9.0         ↓       0.0010
  5     4.86       316.1761             316.1760             0.1           \[M + H\]^+^    C~15~H~25~NO~6~      Derivative of carnitine               3.8         ↑       0.0426
  6     5.48       300.1818             300.1811             0.7           \[M + H\]^+^    C~15~H~25~NO~5~      Derivative of carnitine               4.6         ↑       0.0000
  7     5.55       318.1922             318.1917             0.5           \[M + H\]^+^    C~15~H~27~NO~6~      Derivative of carnitine               7.2         ↑       0.0366
  8     5.71       135.0433             135.0446             −1.1          \[M + H\]^+^    C~8~H~6~O~2~         6Z-Octene-2,4-diynoic acid            8.1         ↓       0.0230
  9     5.98       225.1089             225.1103             −1.4          \[M + Na\]^+^   C~10~H~18~O~4~       Sebacic acid                          2.0         ↓       0.0000
  10    6.29       302.1969             302.1981             −1.2          \[M + H\]^+^    C~15~H~27~NO~5~      Derivative of carnitine               5.7         ↑       0.0039
  11    7.17       284.1844             284.1862             −1.8          \[M + H\]^+^    C~15~H~25~NO~4~      Supinine                              6.9         ↑       0.0039
  12    7.65       161.0599             161.0603             −0.4          \[M + H\]^+^    C~10~H~8~O~2~        1-Formyl-2-indanone                   3.0         ↓       0.0263
  13    7.68       354.2273             354.2280             −0.7          \[M + H\]^+^    C~19~H~31~NO~5~      Derivative of carnitine               3.5         ↑       0.0015
  14    7.71       233.1166             233.1154             1.2           \[M + Na\]^+^   C~12~H~18~O~3~       Jasmonic acid                         2.9         ↑       0.0083
  15    8.00       137.0607             137.0603             0.4           \[M + H\]^+^    C~8~H~8~O~2~         3-Vinylcatechol                       6.6         ↑       0.0019
  16    8.08       330.2264             330.2280             −4.8          \[M + H\]^+^    C~17~H~31~NO~5~      6-Keto-decanoylcarnitine              11.8        ↓       0.0048
  17    8.17       286.2018             286.2018             0.0           \[M + H\]^+^    C~15~H~27~NO~4~      2-Octenoylcarnitine                   26.1        ↑       0.0000
  18    8.31       332.2440             332.2437             0.3           \[M + H\]^+^    C~17~H~33~NO~5~      Derivative of carnitine               3.9         ↑       0.0000
  19    8.32       330.2272             330.2280             −0.8          \[M + H\]^+^    C~17~H~31~NO~5~      6-Keto-decanoylcarnitine              5.7         ↓       0.0077
  20    10.11      356.2424             356.2437             −1.3          \[M + H\]^+^    C~19~H~33~NO~5~      Derivative of carnitine               2.3         ↓       0.0024
  21    10.50      288.2167             288.2175             −0.8          \[M + H\]^+^    C~15~H~29~NO~4~      L-Octanoylcarnitine                   3.9         ↑       0.0027
  22    10.72      358.2587             358.2593             −0.6          \[M + H\]^+^    C~19~H~35~NO~5~      Derivative of carnitine               3.7         ↓       0.0000
  23    12.54      312.2162             312.2175             −1.3          \[M + H\]^+^    C~17~H~29~NO~4~      2-trans,4-cis-Decadienoylcarnitine    9.5         ↓       0.0000
  24    12.62      314.2345             314.2331             1.4           \[M + H\]^+^    C~17~H~31~NO~4~      9-Decenoylcarnitine                   3.1         ↓       0.0242
  25    12.79      312.2169             312.2175             −0.6          \[M + H\]^+^    C~17~H~29~NO~4~      2-trans,4-cis-Decadienoylcarnitine    10.7        ↓       0.0010
  26    13.98      338.2312             338.2307             0.5           \[M + Na\]^+^   C~17~H~33~NO~4~      L-Decanoylcarnitine                   7.7         ↓       0.0001
  27    14.25      338.2310             338.2307             0.3           \[M + Na\]^+^   C~17~H~33~NO~4~      L-Hexanoylcarnitine                   7.6         ↑       0.0000
  28    14.49      338.2321             338.2307             1.4           \[M + Na\]^+^   C~17~H~33~NO~4~      L-Decanoylcarnitine                   7.5         ↓       0.0023
  29    15.93      489.2449             489.2464             −1.5          \[M + Na\]^+^   C~25~H~38~O~8~       Androsterone glucuronide              2.5         ↓       0.0171
  30    17.02      279.2342             279.2324             1.8           \[M + H\]^+^    C~18~H~30~O~2~       *alpha*-Linolenic acid                2.5         ↓       0.0019
  31    0.65       191.0183             191.0192             −0.9          \[M − H\]^−^    C~6~H~8~O~7~         Citric acid                           14.9        ↑       0.0005
  32    0.76       129.0177             129.0188             −1.1          \[M − H\]^−^    C~5~H~6~O~4~         Mesaconic acid                        8.3         ↑       0.0000
  33    0.86       199.0080             199.0099             −1.9          \[M − H\]^−^    C~5~H~12~O~4~S~2~    2-Hydroxypropyl-CoM                   3.5         ↓       0.0000
  34    0.99       232.0275             232.0280             −0.5          \[M − H\]^−^    C~8~H~11~NO~5~S      Dopamine 3-O-sulfate                  2.3         ↓       0.0005
  35    1.03       161.0444             161.0450             −0.6          \[M − H\]^−^    C~6~H~10~O~5~        3-Hydroxy-3-methyl-glutaric acid      3.1         ↑       0.0000
  36    1.11       182.0461             182.0453             0.8           \[M − H\]^−^    C~8~H~9~NO~4~        4-Pyridoxic acid                      2.2         ↑       0.0000
  37    1.43       253.0827             253.0824             0.3           \[M − H\]^−^    C~11~H~14~N~2~O~5~   Nicotinamide riboside                 3.2         ↓       0.0029
  38    2.42       225.0860             225.0875             −1.5          \[M − H\]^−^    C~10~H~14~N~2~O~4~   Porphobilinogen                       3.1         ↓       0.0000
  39    3.49       212.0002             212.0018             −1.6          \[M − H\]^−^    C~8~H~7~NO~4~S       Indoxyl sulfuric acid                 6.0         ↓       0.0000
  40    4.68       263.0994             263.1032             −3.8          \[M − H\]^−^    C~13~H~16~N~2~O~4~   *alpha*-N-Phenylacetyl-L-glutamine    3.7         ↓       0.0007
  41    5.70       187.0048             187.0065             −1.7          \[M − H\]^−^    C~7~H~8~O~4~S        4-Sulfobenzyl alcohol                 4.7         ↓       0.0144
  42    5.79       193.0353             193.0348             0.5           \[M − H\]^−^    C~6~H~10~O~7~        Unknown                               3.2         ↑       0.0001
  43    6.21       377.1456             377.1461             −0.5          \[M − H\]^−^    C~17~H~22~N~4~O~6~   Reduced riboflavin                    6.5         ↓       0.0001
  44    6.39       201.1112             201.1127             −1.5          \[M − H\]^−^    C~10~H~18~O~4~       Sebacic acid                          4.5         ↓       0.0000
  45    6.55       173.0799             173.0814             −1.5          \[M − H\]^−^    C~8~H~14~O~4~        Suberic acid                          2.8         ↓       0.0002
  46    7.53       229.1425             229.1440             −1.5          \[M − H\]^−^    C~12~H~22~O~4~       Dodecanedioic acid                    3.9         ↓       0.0000
  47    7.68       153.0905             153.0916             −1.1          \[M − H\]^−^    C~9~H~14~O~2~        5,7-Nonadienoic acid                  3.0         ↑       0.0000
  48    7.77       225.1595             225.1603             −0.8          \[M − H\]^−^    C~12~H~22~N~2~O~2~   1,8-Diazacyclotetradecane-2,9-dione   2.1         ↓       0.0000
  49    7.78       145.0593             145.0613             −2.0          \[M − H\]^−^    C~5~H~10~N~2~O~3~    L-Glutamine                           7.2         ↓       0.0015
  50    7.96       185.1181             185.1178             0.3           \[M − H\]^−^    C~10~H~18~O~3~       10-oxo-decanoic acid                  3.2         ↓       0.0000
  51    8.06       141.0901             141.0916             −1.5          \[M − H\]^−^    C~8~H~14~O~2~        Unknown                               4.8         ↑       0.0000
  52    8.20       199.0956             199.0970             −1.4          \[M − H\]^−^    C~10~H~16~O~4~       Decenedioic acid                      4.9         ↑       0.0016
  53    9.09       179.1069             179.1072             −0.3          \[M − H\]^−^    C~11~H~16~O~2~       3-tert-Butyl-5-methylcatechol         3.5         ↑       0.0009

[^1]: Academic Editor: Mee-Ra Rhyu
